RFG Advisory LLC Makes New $888,000 Investment in Tarsus Pharmaceuticals, Inc. $TARS

RFG Advisory LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the 3rd quarter, HoldingsChannel.com reports. The firm bought 14,941 shares of the company’s stock, valued at approximately $888,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Osaic Holdings Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after acquiring an additional 2,782 shares in the last quarter. West Wealth Group LLC purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter valued at about $202,000. Valeo Financial Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at about $209,000. Finally, Allianz Asset Management GmbH purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter worth approximately $227,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 3.3%

Shares of NASDAQ:TARS opened at $63.25 on Friday. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $2.68 billion, a PE ratio of -31.31, a P/E/G ratio of 0.94 and a beta of 0.57. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The firm has a fifty day moving average price of $74.70 and a 200 day moving average price of $66.69.

Analysts Set New Price Targets

A number of research analysts recently commented on TARS shares. Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective on the stock. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Barclays started coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, HC Wainwright boosted their target price on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $82.29.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares of the company’s stock, valued at $3,120,535.80. This represents a 15.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 8.97% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.